Linked Life Data

18521282

Source:http://linkedlifedata.com/resource/pubmed/id/18521282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
2008-6-3
pubmed:abstractText
Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15- 25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to confirm the activity of this drug in soft tissue sarcoma.Patients and methods. Thirty-seven patients with soft tissue sarcoma resistant to at least one anthracyclinecontaining regimen were enrolled in a phase II multicenter study evaluating docetaxel 100 mg/m(2) in a 1-h i.v. infusion q(3) weeks.Results.Thirty-seven patients were enrolled onto this phase II study and 36 were evaluable for response. Only one partial remission was observed [2.8% with 95% confidence interval (CI) 0.1- 16.2%]. Median progression-free and overall survival were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous manifestations were the most common toxicities.Discussion. The results of this phase II study do not confirm a previous EORTC repor t on the activity of docetaxel in soft tissue sarcoma, but are consistent with other more recent phase II studies. The accumulated evidence does not justify the use of this drug in the management of patients suffering from this disease, resistant to anthracyclinecontaining regimens.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-1487397, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-18521230, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-1868027, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-2702835, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-3479329, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-3595691, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-7602342, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-7918126, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-8094996, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-8315424, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-8315425, http://linkedlifedata.com/resource/pubmed/commentcorrection/18521282-8931674
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:issn
1357-714X
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
177-81
pubmed:year
1999
pubmed:articleTitle
Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors.
pubmed:affiliation
Italian Group on Rare Tumors c/o Istituto Clinico Humanitas Via Manzoni, 56 Milano Rozzano 20089 Italy.
pubmed:publicationType
Journal Article